WESTLAKE CHEMICAL PARTNERS LP (WLKP) Financials

WLKP

Trailing 12 months to June 30, 2026

Revenue $1.2B +12.1% YoY

Net Income $57.6M +9.4% YoY

Free Cash Flow $409.1M +67.7% YoY

Operating Cash Flow $465.7M +48.6% YoY

Market Cap $746.9M as of Oct 10, 2026

Price / Sales 0.6x on $1.2B revenue, trailing 12 months to June 30, 2026

Price / Earnings 13.0x on $57.6M net income, trailing 12 months to June 30, 2026

Price / Book 1.0x on $769.4M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 10, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 5, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 5, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the WLKP SEC filings page.

WESTLAKE CHEMICAL PARTNERS LP (WLKP) reported $1.2B in revenue over the twelve months to Jun 30, 2026, up 12.1% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 14 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI WLKP FY2025 2026-10-03

The business converts accounting earnings into cash, but FY2025’s margin and cash-flow compression exposed a less forgiving operating year.

Revenue increased 2.7% in FY2025, but operating margin fell to 27.4%, showing that additional sales did not preserve prior profitability. Free-cash-flow margin fell to 17.3% as capital expenditures rose to $78.8M, linking weaker cash conversion to heavier reinvestment.

Cash conversion remains a defining feature: FY2025 operating cash flow reached $280M versus net income of $48.7M, so accounting profit materially understates cash generated before investment. After capital expenditures of $78.8M, free cash flow remained $202M, indicating that the asset base still produces cash beyond maintenance spending.

The balance sheet remains asset-backed, with FY2025 liabilities of $454M against $1.3B of assets, but short-term flexibility narrowed. The current ratio fell from 4.4x in FY2024 to 2.8x in FY2025, leaving less working-capital cushion even as total liabilities stayed broadly stable.

Financial Health Signals

Financial Health Score 73/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of WESTLAKE CHEMICAL PARTNERS LP's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

WESTLAKE CHEMICAL PARTNERS LP has an operating margin of 27.4%, meaning the company retains $27 of operating profit per $100 of revenue. This strong profitability earns a score of 91/100, reflecting efficient cost management and pricing power. This is down from 34.4% the prior year.

Growth

WESTLAKE CHEMICAL PARTNERS LP's revenue grew a modest 2.7% year-over-year to $1.2B. This slow but positive growth earns a score of 27/100.

Leverage

WESTLAKE CHEMICAL PARTNERS LP has a moderate D/E ratio of 0.57. This balance of debt and equity financing earns a leverage score of 58/100.

Liquidity

With a current ratio of 2.80, WESTLAKE CHEMICAL PARTNERS LP holds $2.80 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 76/100.

Cash Flow

WESTLAKE CHEMICAL PARTNERS LP converts 17.3% of revenue into free cash flow ($201.7M). This strong cash generation earns a score of 92/100.

Returns

WESTLAKE CHEMICAL PARTNERS LP earns a strong 6.1% return on equity (ROE), meaning it generates $6 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 96/100. This is down from 7.5% the prior year.

Piotroski F-Score Partial

4/8

WESTLAKE CHEMICAL PARTNERS LP passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 3 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.

Earnings Quality Cash-Backed

5.76x

For every $1 of reported earnings, WESTLAKE CHEMICAL PARTNERS LP generates $5.76 in operating cash flow ($280.5M OCF vs $48.7M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Interest Coverage Safe

13.96x

WESTLAKE CHEMICAL PARTNERS LP earns $13.96 in operating income for every $1 of interest expense ($319.6M vs $22.9M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$297.1M

YoY0.0%

QoQ-2.8%

5Y CAGR-1.6%

10Y CAGR+3.5%

WESTLAKE CHEMICAL PARTNERS LP generated $297.1M in revenue in Q2 2026. That is unchanged from the same quarter a year earlier. Against the prior quarter it is down 2.8%.

EBITDA

$110.2M

YoY-2.3%

QoQ-8.8%

5Y CAGR-5.4%

10Y CAGR+1.0%

WESTLAKE CHEMICAL PARTNERS LP's EBITDA was $110.2M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 2.3% from the same quarter a year earlier. Against the prior quarter it is down 8.8%.

Net Income

$14.2M

YoY-2.2%

QoQ+0.5%

5Y CAGR-10.7%

10Y CAGR+4.3%

WESTLAKE CHEMICAL PARTNERS LP reported $14.2M in net income in Q2 2026. This represents a decrease of 2.2% from the same quarter a year earlier. Against the prior quarter it is up 0.5%.

EPS (Diluted)

Not reported for Q2 2026.

Cash & Balance Sheet

Free Cash Flow

$117.4M

YoY+866.6%

QoQ+12.2%

5Y CAGR0.0%

WESTLAKE CHEMICAL PARTNERS LP generated $117.4M in free cash flow in Q2 2026, representing cash available after capex. This represents an increase of 866.6% from the same quarter a year earlier. Against the prior quarter it is up 12.2%.

Cash & Debt

$49.3M

YoY+34.8%

QoQ+11.4%

5Y CAGR+22.8%

10Y CAGR-10.6%

WESTLAKE CHEMICAL PARTNERS LP held $49.3M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

35M

YoY0.0%

QoQ0.0%

5Y CAGR0.0%

WESTLAKE CHEMICAL PARTNERS LP had 35M shares outstanding in Q2 2026. That is unchanged from the same quarter a year earlier. It is unchanged from the prior quarter.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Gross Margin

31.9%

YoY-0.9pp

QoQ+1.2pp

5Y change-8.8pp

10Y change-10.0pp

WESTLAKE CHEMICAL PARTNERS LP's gross margin was 31.9% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is down 0.9 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.2 percentage points.

Operating Margin

29.4%

YoY-1.3pp

QoQ+1.1pp

5Y change-8.7pp

10Y change-9.8pp

WESTLAKE CHEMICAL PARTNERS LP's operating margin was 29.4% in Q2 2026, reflecting core business profitability. This is down 1.3 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.1 percentage points.

Net Margin

4.8%

YoY-0.1pp

QoQ+0.2pp

5Y change-3.0pp

10Y change+0.4pp

WESTLAKE CHEMICAL PARTNERS LP's net profit margin was 4.8% in Q2 2026, showing the share of revenue converted to profit. This is down 0.1 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.2 percentage points.

Return on Equity

1.8%

YoY+0.1pp

QoQ+0.1pp

5Y change-0.8pp

10Y change+0.8pp

WESTLAKE CHEMICAL PARTNERS LP's ROE was 1.8% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is up 0.1 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.1 percentage points.

Capital Allocation

Capital Expenditures

$12.5M

YoY-48.8%

QoQ+124.6%

5Y CAGR-3.0%

10Y CAGR-17.9%

WESTLAKE CHEMICAL PARTNERS LP invested $12.5M in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 48.8% from the same quarter a year earlier. Against the prior quarter it is up 124.6%.

R&D Spending

Not reported for Q2 2026.

Share Buybacks

Not reported for Q2 2026.

WLKP Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

WLKP quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Revenue	$1.2B	$1.2B+2.7%	$1.1B-4.6%	$1.2B-25.3%	$1.6B+31.1%	$1.2B+25.7%	$966.7M-11.5%	$1.1B-15.1%	$1.3B+9.6%	$1.2B+18.9%	$986.7M-2.0%	$1.0B-42.4%	$1.7B	N/A	N/A
Cost of Revenue	$849.9M	$818.8M+14.2%	$717.0M-10.8%	$803.3M-33.9%	$1.2B+57.3%	$773.2M+31.5%	$587.8M-17.5%	$712.4M-21.6%	$908.5M+18.1%	$769.3M+29.2%	$595.4M-4.6%	$624.3M-37.8%	$1.0B	N/A	N/A
Gross Profit	$384.8M	$347.8M-17.0%	$418.9M+8.1%	$387.5M+2.7%	$377.4M-14.6%	$441.7M+16.6%	$378.9M-0.1%	$379.4M+0.6%	$377.2M-6.6%	$403.7M+3.2%	$391.3M+2.2%	$382.9M-48.7%	$745.8M	N/A	N/A
SG&A Expenses	$29.2M	$28.3M-0.8%	$28.5M-4.2%	$29.8M+0.2%	$29.7M-4.3%	$31.0M+19.8%	$25.9M-11.6%	$29.3M+6.1%	$27.6M-5.7%	$29.3M+17.6%	$24.9M+5.7%	$23.6M-19.5%	$29.3M	N/A	N/A
Operating Income	$355.6M	$319.6M-18.2%	$390.4M+9.2%	$357.7M+2.9%	$347.7M-15.3%	$410.7M+16.3%	$353.0M+0.8%	$350.1M+0.2%	$349.6M-6.6%	$374.4M+2.2%	$366.4M+2.0%	$359.3M-49.9%	$716.6M	N/A	N/A
EBITDA	N/A	$447.6M-10.9%	$502.3M+7.4%	$467.9M-0.2%	$468.8M-9.8%	$519.5M+13.9%	$456.1M-0.3%	$457.5M-0.2%	$458.4M-6.1%	$488.4M+5.1%	$464.7M+5.5%	$440.5M-44.5%	$794.2M	N/A	N/A
Interest Expense	$21.7M	$22.9M-10.9%	$25.7M-3.0%	$26.5M+97.7%	$13.4M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$590K	$547K-34.5%	$835K+2.7%	$813K-20.1%	$1.0M+85.2%	$549K-2.7%	$564K-22.5%	$728K+3209.1%	$22K-98.3%	$1.3M+23.7%	$1.0M+54.0%	$672K-99.7%	$199.4M	N/A	N/A
Net Income	$57.6M	$48.7M-21.9%	$62.4M+14.9%	$54.3M-15.4%	$64.2M-22.3%	$82.5M+24.8%	$66.2M+8.5%	$61.0M+23.6%	$49.3M+1.4%	$48.7M+18.9%	$40.9M+2.8%	$39.8M+193.4%	$13.6M-97.5%	$546.5M+38.0%	$395.9M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$297.1M0.0%	$305.7M+28.6%	$323.0M+11.4%	$308.9M+11.5%	$297.1M+4.6%	$237.6M-16.5%	$290.1M-2.4%	$277.0M-13.9%
Cost of Revenue	$202.3M+1.4%	$211.9M+15.5%	$226.2M+18.2%	$209.5M+30.9%	$199.6M+9.1%	$183.5M+0.6%	$191.5M-2.6%	$160.1M-30.0%
Gross Profit	$94.8M-2.8%	$93.8M+73.4%	$96.8M-1.8%	$99.4M-15.0%	$97.5M-3.7%	$54.1M-47.1%	$98.6M-2.1%	$116.9M+25.8%
SG&A Expenses	$7.5M+19.0%	$7.2M-3.8%	$7.1M+7.5%	$7.4M+2.6%	$6.3M-17.2%	$7.5M+5.6%	$6.6M-16.6%	$7.3M+7.6%
Operating Income	$87.3M-4.3%	$86.6M+85.7%	$89.8M-2.5%	$92.0M-16.1%	$91.2M-2.6%	$46.6M-51.0%	$92.0M-0.9%	$109.7M+27.2%
EBITDA	$110.2M-2.3%	$120.9M+64.1%	$147.1M+11.1%	$113.9M-13.2%	$112.8M-2.3%	$73.7M-40.1%	$132.5M-1.3%	$131.3M+22.1%
Interest Expense	$5.1M-13.3%	$5.1M-8.2%	$5.5M-4.6%	$5.9M-11.2%	$5.9M-11.2%	$5.5M-15.9%	$5.8M	$6.7M
Income Tax	$178K-13.2%	$177K+65.4%	$193K-4.5%	$42K-80.6%	$205K-1.0%	$107K-49.0%	$202K-1.9%	$216K-2.7%
Net Income	$14.2M-2.2%	$14.2M+186.4%	$14.5M-3.0%	$14.7M-19.2%	$14.6M+0.9%	$4.9M-66.6%	$15.0M+4.9%	$18.1M+37.3%

Not reported in any period shown, so not listed: R&D Expenses, EPS (Basic), EPS (Diluted), Diluted Shares (Avg).

WLKP Balance Sheet

WLKP quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Total Assets	$1.3B-2.4%	$1.3B-2.2%	$1.3B-4.0%	$1.4B-7.3%	$1.5B+9.2%	$1.4B-2.7%	$1.4B-4.7%	$1.5B-3.5%	$1.5B-2.6%	$1.6B+20.5%	$1.3B+17.7%	$1.1B+5.3%	$1.0B	N/A
Current Assets	$143.5M-40.4%	$240.9M+6.5%	$226.2M-8.0%	$245.8M-12.6%	$281.2M+6.8%	$263.3M+10.4%	$238.4M-3.5%	$247.1M+6.8%	$231.4M-0.3%	$232.2M+3.1%	$225.3M+14.6%	$196.6M+1.9%	$192.9M	N/A
Cash & Equivalents	$44.3M-24.1%	$58.3M-0.5%	$58.6M-9.5%	$64.8M+279.8%	$17.1M-0.6%	$17.2M-13.9%	$19.9M+0.9%	$19.7M-26.9%	$27.0M-69.6%	$88.9M-47.6%	$169.6M+26.8%	$133.8M	$0	$0
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$2.8M-31.8%	$4.1M-8.4%	$4.4M-6.0%	$4.7M-47.0%	$8.9M+156.1%	$3.5M+39.9%	$2.5M-43.4%	$4.4M-21.5%	$5.6M+42.1%	$3.9M+1.4%	$3.9M-41.5%	$6.6M-94.3%	$116.4M	N/A
Accounts Receivable	N/A	N/A	N/A	$20.0M+243.9%	$5.8M-47.2%	$11.0M+11.2%	$9.9M	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$5.8M0.0%	$5.8M0.0%	$5.8M0.0%	$5.8M0.0%	$5.8M0.0%	$5.8M0.0%	$5.8M0.0%	$5.8M0.0%	$5.8M0.0%	$5.8M0.0%	$5.8M0.0%	$5.8M	N/A	N/A
Total Liabilities	$454.2M-1.0%	$458.6M-0.4%	$460.6M-1.6%	$468.3M-7.8%	$508.0M+15.1%	$441.4M0.0%	$441.3M-16.4%	$528.0M+2.2%	$516.5M-18.6%	$634.3M+43.1%	$443.2M+69.5%	$261.5M-55.4%	$586.0M	N/A
Current Liabilities	$51.3M-7.4%	$55.4M-1.7%	$56.3M-15.8%	$66.9M-37.3%	$106.8M+168.6%	$39.8M+2.3%	$38.8M-20.3%	$48.8M+21.2%	$40.2M+6.5%	$37.8M-34.5%	$57.7M+80.4%	$32.0M-78.6%	$149.3M	N/A
Non-Current Liabilities	$402.9M-0.1%	$403.3M-0.2%	$404.3M+0.7%	$401.3M0.0%	$401.2M-0.1%	$401.6M-0.2%	$402.5M-16.0%	$479.3M+0.6%	$476.3M-20.2%	$596.5M+54.7%	$385.5M+68.0%	$229.5M-47.5%	$436.8M	N/A
Total Equity	$802.4M-3.3%	$829.3M-3.1%	$856.3M-5.3%	$903.7M-7.1%	$972.7M+6.3%	$915.1M-3.9%	$952.1M+1.9%	$934.1M-6.5%	$998.7M+8.4%	$921.0M+8.7%	$847.2M+1.5%	$835.0M+83.3%	$455.4M	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$1.2B-6.9%	$1.2B-9.9%	$1.3B-2.4%	$1.3B-1.8%	$1.3B+1.5%	$1.4B+5.9%	$1.3B-2.2%	$1.3B-3.5%
Current Assets	$157.5M+0.6%	$148.9M-33.9%	$143.5M-40.4%	$130.9M-45.8%	$156.5M-32.6%	$225.2M+0.4%	$240.9M+6.5%	$241.6M+4.4%
Cash & Equivalents	$49.3M+34.8%	$44.3M-10.7%	$44.3M-24.1%	$37.9M-37.0%	$36.6M-44.6%	$49.6M-11.0%	$58.3M-0.5%	$60.2M-8.6%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$3.6M+9.3%	$3.1M+13.2%	$2.8M-31.8%	$3.1M-17.9%	$3.3M-27.3%	$2.7M-43.8%	$4.1M-8.4%	$3.8M-14.6%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	$5.8M0.0%	$5.8M0.0%	$5.8M0.0%	$5.8M0.0%	$5.8M0.0%	$5.8M0.0%	$5.8M0.0%	$5.8M0.0%
Total Liabilities	$447.9M-5.9%	$443.3M-22.0%	$454.2M-1.0%	$458.3M+0.3%	$476.0M+5.0%	$568.2M+27.2%	$458.6M-0.4%	$456.9M-4.9%
Current Liabilities	$45.8M-37.2%	$40.8M-75.3%	$51.3M-7.4%	$55.1M+3.4%	$72.9M+47.0%	$164.8M+282.6%	$55.4M-1.7%	$53.3M-29.5%
Non-Current Liabilities	$402.2M-0.2%	$402.5M-0.2%	$402.9M-0.1%	$403.2M-0.1%	$403.1M-0.2%	$403.4M-0.1%	$403.3M-0.2%	$403.6M-0.3%
Total Equity	$769.4M-7.4%	$792.4M-1.3%	$802.4M-3.3%	$813.3M-2.9%	$831.2M-0.4%	$803.1M-5.3%	$829.3M-3.1%	$837.8M-2.7%

Not reported in any period shown, so not listed: Accounts Receivable, Long-Term Debt, Retained Earnings.

WLKP Cash Flow Statement

WLKP quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Operating Cash Flow	$465.7M	$280.5M-42.2%	$485.0M+7.3%	$452.0M-2.5%	$463.7M+13.5%	$408.4M+9.4%	$373.4M-17.2%	$450.8M+3.4%	$436.2M-18.8%	$537.4M+86.8%	$287.7M-36.4%	$452.5M-25.1%	$604.0M	N/A	N/A
Depreciation & Amortization	N/A	$128.0M+14.4%	$111.9M+1.5%	$110.2M-9.0%	$121.1M+11.3%	$108.8M+5.5%	$103.2M-3.9%	$107.3M-1.4%	$108.8M-4.5%	$114.0M+16.1%	$98.2M+20.9%	$81.2M+4.6%	$77.6M+35.4%	$57.3M+7.9%	$53.1M
Capital Expenditures	$56.5M	$78.8M+60.9%	$49.0M+4.6%	$46.8M-13.5%	$54.1M-33.3%	$81.2M+119.6%	$37.0M-15.4%	$43.7M+9.6%	$39.9M-42.1%	$68.9M-77.0%	$299.6M+29.6%	$231.2M+14.0%	$202.8M	N/A	N/A
Free Cash Flow	$409.1M	$201.7M-53.8%	$436.0M+7.6%	$405.2M-1.1%	$409.6M+25.2%	$327.3M-2.7%	$336.4M-17.4%	$407.1M+2.7%	$396.3M-15.4%	$468.5M+4033.0%	-$11.9M-105.4%	$221.4M-44.8%	$401.2M	N/A	N/A
Investing Cash Flow	-$56.5M	$31.2M+135.0%	-$89.0M-17.2%	-$75.9M-532.7%	-$12.0M+81.3%	-$64.3M-3264.4%	$2.0M+103.5%	-$57.7M-11.4%	-$51.8M+74.5%	-$203.2M+32.1%	-$299.5M-29.5%	-$231.2M-13.9%	-$203.0M	N/A	N/A
Financing Cash Flow	-$396.4M	-$325.7M+17.8%	-$396.3M-3.7%	-$382.2M+5.4%	-$404.0M-17.4%	-$344.2M+9.0%	-$378.2M+3.7%	-$392.9M-0.3%	-$391.6M+1.1%	-$396.0M-474.7%	-$68.9M+62.9%	-$185.5M+30.6%	-$267.3M	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	$129.8M+1331.5%	$110.2M+140.7%	$120.4M-9.1%	$105.2M-16.5%	$9.1M-92.6%	$45.8M-56.2%	$132.5M+23.0%	$126.1M+24.9%
Depreciation & Amortization	$22.9M+6.1%	$34.3M+26.7%	$34.6M+25.8%	$22.0M+1.6%	$21.6M-1.1%	$27.1M-3.3%	$27.5M-2.9%	$21.6M+1.6%
Capital Expenditures	$12.5M-48.8%	$5.6M-65.2%	$8.8M-34.5%	$29.7M+90.7%	$24.4M+139.5%	$16.0M+63.3%	$13.5M+4.9%	$15.5M-7.5%
Free Cash Flow	$117.4M+866.6%	$104.6M+250.9%	$111.5M-6.3%	$75.6M-31.6%	-$15.3M-113.7%	$29.8M-68.5%	$119.0M+25.5%	$110.5M+31.4%
Investing Cash Flow	-$19.5M-154.7%	-$18.6M-232.1%	-$18.8M+51.1%	$348K+101.1%	$35.6M+450.0%	$14.0M+243.7%	-$38.5M-68.4%	-$30.5M-348.5%
Financing Cash Flow	-$105.3M-82.4%	-$91.6M-33.7%	-$95.2M+0.7%	-$104.2M-2.9%	-$57.7M+43.1%	-$68.5M+29.8%	-$95.9M-4.1%	-$101.3M-15.6%

Not reported in any period shown, so not listed: Stock-Based Compensation, Dividends Paid, Share Buybacks.

WLKP Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

WLKP quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K
Gross Margin	29.8%-7.1pp	36.9%+4.3pp	32.5%+8.9pp	23.7%-12.7pp	36.4%-2.8pp	39.2%+4.4pp	34.8%+5.4pp	29.3%-5.1pp	34.4%-5.2pp	39.7%+1.7pp	38.0%-4.6pp	42.6%	N/A	N/A
Operating Margin	27.4%-7.0pp	34.4%+4.3pp	30.0%+8.2pp	21.8%-12.0pp	33.8%-2.7pp	36.5%+4.5pp	32.1%+4.9pp	27.2%-4.7pp	31.9%-5.2pp	37.1%+1.5pp	35.7%-5.3pp	40.9%	N/A	N/A
Net Margin	4.2%-1.3pp	5.5%+0.9pp	4.6%+0.5pp	4.0%-2.8pp	6.8%-0.1pp	6.8%+1.3pp	5.6%+1.8pp	3.8%-0.3pp	4.2%0.0pp	4.2%+0.2pp	4.0%+3.2pp	0.8%	N/A	N/A
Return on Equity	6.1%-1.5pp	7.5%+1.2pp	6.3%-0.8pp	7.1%-1.4pp	8.5%+1.3pp	7.2%+0.8pp	6.4%+1.1pp	5.3%+0.4pp	4.9%+0.4pp	4.5%-0.3pp	4.7%+3.1pp	1.6%-118.4pp	120.0%	N/A
Return on Assets	3.9%-1.0pp	4.8%+0.7pp	4.1%-0.6pp	4.7%-0.9pp	5.6%+0.7pp	4.9%+0.5pp	4.4%+1.0pp	3.4%+0.2pp	3.2%+0.6pp	2.6%-0.5pp	3.1%+1.9pp	1.2%-51.2pp	52.5%	N/A
Current Ratio	2.80-1.6x	4.35+0.3x	4.02+0.3x	3.67+1.0x	2.63-4.0x	6.62+0.5x	6.14+1.1x	5.07-0.7x	5.75-0.4x	6.15+2.2x	3.90-2.2x	6.15+4.9x	1.29	N/A
Debt-to-Equity	0.570.0x	0.550.0x	0.540.0x	0.520.0x	0.520.0x	0.480.0x	0.46-0.1x	0.570.0x	0.52-0.2x	0.69+0.2x	0.52+0.2x	0.31-1.0x	1.29	N/A
Asset Turnover	0.930.0x	0.880.0x	0.90-0.3x	1.16+0.3x	0.82+0.1x	0.71-0.1x	0.78-0.1x	0.88+0.1x	0.77+0.1x	0.63-0.1x	0.78-0.8x	1.60	N/A	N/A
FCF Margin	17.3%-21.1pp	38.4%+4.4pp	34.0%+8.3pp	25.7%-1.2pp	26.9%-7.9pp	34.8%-2.5pp	37.3%+6.5pp	30.8%-9.1pp	39.9%+41.1pp	-1.2%-23.2pp	22.0%-1.0pp	22.9%	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Gross Margin	31.9%-0.9pp	30.7%+7.9pp	30.0%-4.0pp	32.2%-10.0pp	32.8%-2.8pp	22.8%-13.1pp	34.0%+0.1pp	42.2%+13.3pp
Operating Margin	29.4%-1.3pp	28.3%+8.7pp	27.8%-4.0pp	29.8%-9.8pp	30.7%-2.2pp	19.6%-13.8pp	31.7%+0.5pp	39.6%+12.8pp
Net Margin	4.8%-0.1pp	4.6%+2.6pp	4.5%-0.7pp	4.7%-1.8pp	4.9%-0.2pp	2.1%-3.1pp	5.2%+0.4pp	6.6%+2.4pp
Return on Equity	1.8%+0.1pp	1.8%+1.2pp	1.8%0.0pp	1.8%-0.4pp	1.8%0.0pp	0.6%-1.1pp	1.8%+0.1pp	2.2%+0.6pp
Return on Assets	1.2%+0.1pp	1.1%+0.8pp	1.2%0.0pp	1.1%-0.3pp	1.1%0.0pp	0.4%-0.8pp	1.2%+0.1pp	1.4%+0.4pp
Current Ratio	3.44+1.3x	3.65+2.3x	2.80-1.6x	2.37-2.2x	2.15-2.5x	1.37-3.8x	4.35+0.3x	4.53+1.5x
Debt-to-Equity	0.580.0x	0.56-0.1x	0.570.0x	0.560.0x	0.570.0x	0.71+0.2x	0.550.0x	0.550.0x
Asset Turnover	0.240.0x	0.25+0.1x	0.260.0x	0.240.0x	0.230.0x	0.170.0x	0.230.0x	0.210.0x
FCF Margin	39.5%+44.6pp	34.2%+21.7pp	34.5%-6.5pp	24.5%-15.4pp	-5.1%-44.5pp	12.6%-20.8pp	41.0%+9.1pp	39.9%+13.8pp

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
WESTLAKE CHEMICAL PARTNERS LP WLKP	FY2025	$1.2B	$48.7M	4.2%	$746.9M	73/100
TRONOX LIMITED CL A TROX	FY2025	$2.9B	-$470.0M	-16.2%	$579.7M	30/100
ASP Isotopes Inc. ASPI	FY2025	$23.8M	-$159.8M	N/A	$406.3M	51/100
AdvanSix Inc. ASIX	FY2025	$1.5B	$49.3M	3.2%	$438.5M	21/100
REX American Resources Corp. REX	FY2025	$650.5M	$83.0M	12.8%	$1.4B	37/100
Green Plains, Inc. GPRE	FY2025	$2.1B	-$121.3M	-5.8%	$1.0B	26/100

Where WESTLAKE CHEMICAL PARTNERS LP Ranks

Frequently Asked Questions

What is WESTLAKE CHEMICAL PARTNERS LP's annual revenue?

WESTLAKE CHEMICAL PARTNERS LP (WLKP) reported $1.2B in total revenue for fiscal year 2025. This represents a 2.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is WESTLAKE CHEMICAL PARTNERS LP's revenue growing?

WESTLAKE CHEMICAL PARTNERS LP (WLKP) revenue grew by 2.7% year-over-year, from $1.1B to $1.2B in fiscal year 2025.

Is WESTLAKE CHEMICAL PARTNERS LP profitable?

Yes, WESTLAKE CHEMICAL PARTNERS LP (WLKP) reported a net income of $48.7M in fiscal year 2025, with a net profit margin of 4.2%.

What is WESTLAKE CHEMICAL PARTNERS LP's EBITDA?

WESTLAKE CHEMICAL PARTNERS LP (WLKP) had EBITDA of $447.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is WESTLAKE CHEMICAL PARTNERS LP's gross margin?

WESTLAKE CHEMICAL PARTNERS LP (WLKP) had a gross margin of 29.8% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is WESTLAKE CHEMICAL PARTNERS LP's operating margin?

WESTLAKE CHEMICAL PARTNERS LP (WLKP) had an operating margin of 27.4% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is WESTLAKE CHEMICAL PARTNERS LP's net profit margin?

WESTLAKE CHEMICAL PARTNERS LP (WLKP) had a net profit margin of 4.2% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is WESTLAKE CHEMICAL PARTNERS LP's return on equity (ROE)?

WESTLAKE CHEMICAL PARTNERS LP (WLKP) has a return on equity of 6.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is WESTLAKE CHEMICAL PARTNERS LP's free cash flow?

WESTLAKE CHEMICAL PARTNERS LP (WLKP) generated $201.7M in free cash flow during fiscal year 2025. This represents a -53.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is WESTLAKE CHEMICAL PARTNERS LP's operating cash flow?

WESTLAKE CHEMICAL PARTNERS LP (WLKP) generated $280.5M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are WESTLAKE CHEMICAL PARTNERS LP's total assets?

WESTLAKE CHEMICAL PARTNERS LP (WLKP) had $1.3B in total assets as of fiscal year 2025, including both current and long-term assets.

What are WESTLAKE CHEMICAL PARTNERS LP's capital expenditures?

WESTLAKE CHEMICAL PARTNERS LP (WLKP) invested $78.8M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How many shares does WESTLAKE CHEMICAL PARTNERS LP have outstanding?

WESTLAKE CHEMICAL PARTNERS LP (WLKP) had 35M shares outstanding as of fiscal year 2025.

What is WESTLAKE CHEMICAL PARTNERS LP's current ratio?

WESTLAKE CHEMICAL PARTNERS LP (WLKP) had a current ratio of 2.80 as of fiscal year 2025, which is generally considered healthy.

What is WESTLAKE CHEMICAL PARTNERS LP's debt-to-equity ratio?

WESTLAKE CHEMICAL PARTNERS LP (WLKP) had a debt-to-equity ratio of 0.57 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is WESTLAKE CHEMICAL PARTNERS LP's return on assets (ROA)?

WESTLAKE CHEMICAL PARTNERS LP (WLKP) had a return on assets of 3.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is WESTLAKE CHEMICAL PARTNERS LP's P/E ratio?

WESTLAKE CHEMICAL PARTNERS LP (WLKP) trades at 13.0x earnings, its market capitalization divided by net income of $57.6M net income, trailing 12 months to June 30, 2026. The market capitalization is $746.9M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is WESTLAKE CHEMICAL PARTNERS LP's price-to-sales ratio?

WESTLAKE CHEMICAL PARTNERS LP (WLKP) trades at 0.6x sales, its market capitalization divided by revenue of $1.2B revenue, trailing 12 months to June 30, 2026. The market capitalization is $746.9M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is WESTLAKE CHEMICAL PARTNERS LP's Piotroski F-Score?

WESTLAKE CHEMICAL PARTNERS LP (WLKP) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are WESTLAKE CHEMICAL PARTNERS LP's earnings high quality?

WESTLAKE CHEMICAL PARTNERS LP (WLKP) has an earnings quality ratio of 5.76x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can WESTLAKE CHEMICAL PARTNERS LP cover its interest payments?

WESTLAKE CHEMICAL PARTNERS LP (WLKP) has an interest coverage ratio of 13.96x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is WESTLAKE CHEMICAL PARTNERS LP?

WESTLAKE CHEMICAL PARTNERS LP (WLKP) scores 73 out of 100 on our Financial Health Score, indicating strong standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.